COVID-19 Diagnosis Linked to Increased Venous Thrombosis Risk in Cancer Patients
A nationwide cohort study found COVID-19 was associated with increased 30-day venous thromboembolism risk in cancer patients treated with bevacizumab.
A nationwide cohort study found COVID-19 was associated with increased 30-day venous thromboembolism risk in cancer patients treated with bevacizumab.
A comprehensive review identifies the biological checkpoints and physical barriers regulating CD8⁺ T cell infiltration in cancer and outlines sequential ...
A phase II trial protocol outlines an interventional chemotherapy and immunotherapy regimen for advanced hepatocellular carcinoma.
A Phase 1 trial demonstrates that the selective GLS1 inhibitor IACS-6274 combined with paclitaxel and bevacizumab achieved tumor shrinkage in ...
In a phase I trial of fourteen patients with advanced ovarian cancer, the investigational glutaminase-1 inhibitor IACS-6274 combined with bevacizumab ...
A 24-month comparative study demonstrates that combining computer-assisted Navilas navigated laser photocoagulation with intravitreal bevacizumab reduces anti-VEGF injection burden by ...
A review indicates that vascular endothelial dysfunction and blood pressure elevation jointly contribute to proteinuria during VEGF inhibitor cancer therapy.
A case report details how a patient with recurrent ovarian cancer developed early-onset duodenal perforation during bevacizumab chemotherapy amid concurrent ...
A large retrospective study in Japan found no significant difference in venous thromboembolism risk between cancer patients receiving a bevacizumab ...
A case report describes recurrent intraocular inflammation following faricimab and aflibercept 8 mg despite prior uneventful tolerance of lower and ...
© 2026 Scienmag - Science Magazine
© 2026 Scienmag - Science Magazine